Mutations in the BRCA1-interacting DEAH helicase Brip1 confer an increased risk of breast cancer. In the present study we aimed to unravel the transcriptional control of Brip1 and to determine its expression levels in a set of 101 primary invasive breast carcinomas. Transcription of Brip1 was found to be cell growth-related and controlled by the E2F/retinoblastoma (Rb) pathway through a conserved E2F-responsive site. Repression of Brip1 expression by the cell growth-inhibiting compound 1a,25-dihydroxyvitamin D 3 depended on this same E2F-responsive site. In spite of its role as a tumor suppressor, both quantitative reverse transcriptase-PCR analyses and immunohistochemical stainings showed significantly elevated Brip1 expression levels in grade 3 tumors as compared to grade 1 or 2 carcinomas. Furthermore, increased Brip1 transcript levels were found in tumors with an estrogen receptor-negative, progesterone receptornegative or HER-2-positive status. In conclusion, these data show that Brip1 is a genuine target gene for the E2F/ Rb pathway and that elevated expression levels of Brip1 are detected in primary invasive breast carcinomas with unfavorable characteristics.
Introduction
Breast cancer is the most common malignancy in Western women and incidence is almost twice as high in first-degree relatives of affected women as in the general population. Known 'high risk' breast cancer susceptibility genes (for example, BRCA1, BRCA2 and TP53) can only account for approximately 25% of familial breast cancer risk. Combined mutations in 'low' to 'moderate' risk susceptibility genes most probably underlie the remaining majority of breast cancer cases (Pharoah et al., 2002) ; hence the need to identify these additional susceptibility genes. On the basis of its interaction with BRCA1, the tumor suppressor Brip1 is considered a potential breast cancer susceptibility gene (Cantor et al., 2001) .
The DEAH helicase family member Brip1 was first identified as a 130 kDa protein directly interacting with the BRCA1 C-terminal (BRCT) domains of BRCA1; hence the name Brip1 (BRCA1-interacting protein) or BACH1 (BRCA1-associated C-terminal Helicase). The Brip1/BRCA1 interaction was found to contribute to the DNA repair activity of BRCA1 (Cantor et al., 2001) . Furthermore, the complex between BRCA1 and phosphorylated Brip1 plays an important role in DNA damage-induced checkpoint control at G 2 to M transition (Yu et al., 2003) . However, avian DT40 B cells in which Brip1 was knocked out, showed a high sensitivity to cisplatin, a DNA-crosslinking agent. Interestingly, this phenotype could be reversed by the overexpression of Brip1 missing the BRCT-interacting domain (required for BRCA1 interaction) but not by overexpression of Brip1 with a point mutation in the helicase domain. These findings show that Brip1 can act in DNA crosslink damage repair in a BRCA1-independent manner (Bridge et al., 2005) . The pronounced sensitivity of cells lacking Brip1 to DNA crosslink damage is highly similar to the phenotype of cells from Fanconi anemia (FA) patients (Ishida and Buchwald 1982; Poll et al., 1982) . FA is a rare chromosomal instability disorder characterized by congenital abnormalities, bone marrow failure and predisposition to cancer (reviewed in D' Andrea and Grompe, 2003) . The FA pathway is crucial for chromosomal integrity maintenance and consists of at least 13 proteins (FANCA-FANCN) . Brip1 is the defective gene in FA complementation group J (FANCJ) (Levitus et al., 2005; Levran et al., 2005; Litman et al., 2005) .
In an initial study of a cohort of 65 women suffering from early onset breast cancer, two individuals were found each carrying a different germ line mutation in the helicase domain of Brip1, while not having mutations in BRCA1 or BRCA2 (Cantor et al., 2001) . The first mutation (P47A) gives rise to a loss of function, whereas the second (M299I) abolishes the ability of Brip1 to unwind longer DNA substrates (Cantor et al., 2004) . In a large scale study, again in breast cancer patients lacking BRCA1/BRCA2 mutations, truncating mutations of Brip1 were found to be low-penetrance susceptibility alleles conferring a twofold relative risk of breast cancer (Seal et al., 2006) . These data clearly point toward Brip1 as being a breast cancer susceptibility gene.
However, little is known about the transcriptional control of Brip1 and its expression levels in human breast cancer. It has been described that transcription of genes involved in processes such as DNA replication, DNA damage repair and checkpoint control is mainly controlled by E2F transcription factors (reviewed in Bracken et al., 2004) . Therefore, we generated mutation constructs of the 5 0 flanking region of the Brip1 gene to determine whether Brip1 is a genuine E2F target. In addition, transcript levels of Brip1 were measured in 101 primary invasive breast carcinomas and compared with E2F1 transcript levels. Moreover, Brip1 transcript levels were correlated with tumor grade, expression of estrogen receptor (ER) and progesterone receptor (PR) and with HER-2 status.
Results
Brip1 transcription is controlled by E2F through a conserved E2F binding site Growth-regulated expression of a gene is often a first indication for control by the E2F/retinoblastoma (Rb) pathway. Therefore, transcript levels of Brip1 were measured by quantitative reverse transcriptase (qRT)-PCR in serum-starved, growth-arrested cells at different time points after addition of serum. For this purpose, mouse osteoblastic MC3T3-E1 cells were used, which are readily growth-arrested and synchronized in G 1 phase after serum deprivation. Starting at 12 h after Figure 1a ). The observed growth-regulated expression of Brip1 was highly similar to the cell growthdependent induction of the cell division cycle 6 homolog (Cdc6), a gene that has been described to be an E2F target gene (Figure 1b ) (Yan et al., 1998; Giangrande et al., 2004) . Also in serum-starved human breast cancer MCF7 cells, addition of serum caused an induction of Brip1 expression, both at the mRNA ( Figure 1c , maximal 2.3-fold induction at 24 h) and the protein (Figure 1d ) level. Next, we cloned a 285 bp proximal promoter fragment of the murine Brip1 gene (positions À216 to þ 69) containing at least seven putative E2F binding sites and determined the responsiveness of this promoter fragment to overexpression of different E2F transcription factors. This 'wild-type' (wt) promoter fragment showed clear responsiveness to overexpression of the transcriptional activators E2F1, E2F2 and E2F3, whereas reporter gene activity was not induced upon overexpression of the transcription repressors E2F4 and E2F5 (Figure 2a ). Chromatin immunoprecipitation (ChIP) assays on nontransfected MC3T3-E1 cells confirmed the E2F responsiveness of the murine Brip1 promoter and showed actual association of the E2F1 transcription factor with the Brip1 promoter ( Figure 2b ). Subsequently, we generated a series of deletion and mutation constructs of the wt promoter fragment affecting the seven putative E2F binding sites either individually or in a combinatorial way and tested these constructs for their responsiveness to E2F overexpression (data not shown). Only when the E2F binding site surrounding the transcription start site (TSS) was mutated (mut construct), reporter gene activity was completely lost (Figure 2a ). Genomic alignment of the 5 0 flanking regions of mouse, rat and human Brip1 revealed that this site is highly conserved between these species (Figure 2c ). To determine its importance in the regulation of Brip1 expression in human breast cancer MCF7 cells, we cloned a 352 bp fragment of the 5 0 flanking region of the human Brip1 gene containing this conserved E2F binding site (located further upstream relative to the TSS compared to the murine promoter). This wt fragment showed clear responsiveness to E2F overexpression, which was significantly decreased upon mutation of the conserved E2F binding site ( Figure 2d ). However, combined mutations of the conserved E2F binding site with one or more of the other putative E2F binding sites that are present in the promoter fragments could possibly lead to an even further decrease in reporter gene activity.
The next aim was to determine the activity of the wt and mut Brip1 promoter constructs under a growthinhibitory stimulus, which acts through the E2F/Rb pathway. 1a,25-Dihydroxyvitamin D 3 (1,25-(OH) 2 D 3 ), the biologically most active form of vitamin D 3 , has a strong antiproliferative action on MC3T3-E1 cells, an effect that has previously been shown to be mediated by E2F/Rb (Eelen et al., 2004b) . Therefore, the expression of Brip1 was first measured by qRT-PCR in MC3T3-E1 cells at different time points after treatment of the cells with 10 À8 M 1,25-(OH) 2 D 3 . At 6 h after treatment, the ratio of Brip1 expression in 1,25-(OH) 2 D 3 -treated cells over Brip1 expression in vehicle-treated cells started to decline significantly (0.73 at 6 h) and at 48 h after treatment the ratio was reduced to 0.12 ( Figure 3a ). These data indicate that the growth-inhibitory action of 1,25-(OH) 2 D 3 is accompanied by a clear and sustained repression of Brip1 expression. The effect of 1,25-(OH) 2 D 3 on Brip1 expression was highly similar to the effect on the Cdc6 gene ( Figure 3b ) which was previously shown to be repressed by 1,25-(OH) 2 D 3 (Eelen et al., 2004a, b) . To determine if repression of Brip1 expression by 1,25-(OH) 2 D 3 is mediated by the same putative E2F binding site as the one that proved most crucial for E2F responsiveness, we transfected the wt and the mutated (mut) Brip1 promoter constructs into MC3T3-E1 cells, which were then treated with 10 À8 M 1,25-(OH) 2 D 3 . This treatment clearly repressed the promoter activity of the wt construct. However, upon mutation of the conserved E2F binding site, the inhibitory effect of 1,25-(OH) 2 D 3 was lost (Figure 3c ).
Brip1 expression in primary invasive breast carcinomas
Brip1 transcript levels were measured by qRT-PCR in a set of 101 primary invasive breast carcinomas composed of 75 invasive ductal carcinomas (IDC), 20 invasive lobular carcinomas (ILC) and 6 invasive tubular carcinomas (Figure 4a ). Brip1 expression was found to be significantly higher in histological grade 3 tumors than in grade 1 and 2 tumors (unadjusted Po0.0001). ER-negative as well as PR-negative carcinomas had higher Brip1 transcript levels as compared to ERpositive and PR-positive tumors, respectively (unadjusted Po0.0001 for ER and for PR). Interestingly, an HER-2-positive status corresponded with higher Brip1 expression than an HER-2-negative status, albeit with less statistical power (unadjusted Po0.005) than the differences observed for ER and PR status. On the basis of the findings that Brip1 expression is controlled by the E2F/Rb pathway, we next compared the Brip1 transcript levels (Figure 4a ) in the set of 101 primary invasive breast carcinomas with the expression of E2F1 (Figure 4b ) but also with the expression of the proliferation marker Ki67 (Figure 4c ), both of which were determined previously . The same as for Brip1, transcript levels of both E2F1 and Ki67 were also higher in grade 3 than in grade 1 or 2 tumors, higher in ER-negative than in ER-positive tumors and higher in PR-negative than in PR-positive specimens. The differences in expression between ERnegative and -positive tumors and PR-negative and -positive tumors is much more pronounced for Ki67 (Figure 4c ) than for E2F1 (Figure 4b ) and Brip1 (Figure 4a ). In contrast, for differences in expression levels between HER-2-positive and HER-2-negative carcinomas, only Brip1 has a P-value below 0.005. Finally, Brip1 (Figure 4d ) and E2F1 (Figure 4e ) protein levels were determined by immunohistochemistry in 30 random cases. Nuclear Brip1 staining was found in 38.5% of grade 1/2 tumors and in 94.1% of grade 3 tumors. Score 3 þ (strong staining intensity in >50% of tumor nuclei) was only seen in grade 3 tumors (23.5% of grade 3 tumors vs 0% of grade 1/2 tumors). Likewise, score 3 þ for nuclear E2F1 staining could only be seen in grade 3 tumors (29.5% of grade 3 tumors vs 0% of grade 1/2 tumors).
Discussion
Breast cancer remains the most common malignancy in Western women. The search for new susceptibility genes continues to be a central topic in breast cancer research. A gene that was recently identified as a breast cancer 
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Transcriptional regulation of Brip1 by E2F G Eelen et al Figure 2 Identification of a functional E2F binding site in the 5 0 flanking region of murine and human Brip1. MC3T3-E1 (a) and MCF7 cells (d) were transfected with pGL3basic containing either a wild-type (wt) or a mutated (mut) fragment of the 5 0 flanking region of murine or human Brip1 (or with empty pGL3basic vector as control) together with expression constructs for different E2F transcription factors (or with corresponding empty control vector) and a b-galactosidase-expressing construct. Luciferase activity was measured 48 h after transfection and was normalized to b-galactosidase activity. Normalized luciferase activities for different luciferase reporter constructs were standardized against control empty luciferase reporter vector pGL3basic. Induction of luciferase activity by overexpression of different E2F transcription factors was expressed relative to empty control expression constructs. RLU, relative luciferase units. Arrow indicates transcription start site (TSS), numbers indicate positions relative to TSS, black circles represent putative E2F-binding sites, white circles indicate mutated E2F binding sites. Bars represent average of at least three independent experiments ± s.e. An asterisk (n) indicates RLU different from RLU for the wt fragment when the same E2F transcription factor is overexpressed, according to Fisher's least significant difference (LSD) multiple-comparison test (a ¼ 0.05). (b) Chromatin immunoprecipitation (ChIP) assays were performed on chromatin from exponentially growing MC3T3-E1 cells with an antibody against E2F1 and control nonspecific rabbit anti-mouse immunoglobulins (IgG). Enriched DNA was amplified with primers, which span the TSS of the Brip1 gene (Brip1 prom.). Primers specific for intron 4 of the Brip1 gene (Brip1 intron) and primers specific for the Cdc6 promoter were used as negative and positive controls, respectively. Results shown are representative for three independent experiments. (c) Conservation of the functional E2F binding site. Genomic alignment of the murine and rat 5 0 flanking region of the Brip1 gene against the human sequence was taken from the EnsEMBL Genome Browser (EnsEMBL release 48). Gray boxes indicate sequence conservation between mouse, rat and human. Open square delineates conserved E2F binding site. susceptibility gene is the DEAH helicase BRCA1-interacting protein Brip1, also known as BACH1. Two independent germ line point mutations in the helicase domain of Brip1 leading to complete or partial loss of function were linked with early onset breast cancer in individuals without BRCA1 or BRCA2 mutations (Cantor et al., 2001) . In addition, also a monoallelic truncation of Brip1 confers breast cancer susceptibility (Seal et al., 2006) . Moreover, Brip1 is the defective gene in FANCJ (Levitus et al., 2005; Levran et al., 2005; Litman et al., 2005) . All these findings underline the possible tumor suppressor role of Brip1.
Because little is known about transcriptional control of the Brip1 gene and its transcript levels in breast carcinomas, we used mutation constructs of the 5 0 flanking region of both the murine and the human Brip1 gene to show that its expression is controlled by the E2F/Rb pathway through a conserved E2F binding site.
The same binding site proved necessary for repression of Brip1 expression by 1,25-(OH) 2 D 3 , an antiproliferative compound that acts through the E2F/Rb pathway (reviewed in Eelen et al., 2007) . However, further study of both the murine and the human Brip1 promoter is needed to determine if other regulatory elements-either combinations of one or more of the other putative E2F binding elements that are present in both promoters or other regulatory elements in general-collaborate with the conserved E2F binding site to control Brip1 expression. The transcript levels of Brip1 were determined in a set of 101 primary invasive breast carcinomas and were found to be significantly higher in grade 3 tumors compared to grade 1 or 2 tumors. Brip1 transcript levels also correlated with a negative ER and PR status and a positive HER-2 status, although the latter had less statistical significance. Transcript levels of both E2F1 and Ki67, measured in the same set Transcriptional regulation of Brip1 by E2F G Eelen et al of primary invasive carcinomas, were also significantly higher in high grade tumors, in ER-negative and in PRnegative tumors. Immunohistochemistry indeed showed a higher overall frequency and intensity of both nuclear Brip1 and E2F1 staining for grade 3 tumors. The similarity in expression profile for Brip1 and E2F1 supports our findings of Brip1 being a direct E2F target gene and suggests co-regulated expression of Brip1 and E2F1 in breast cancer tissues. Co-regulation of E2F1 and Ki67 has been shown before (Zhang et al., 2000; Saiz et al., 2002) and microarray studies have shown the existence of a cluster of 'proliferation genes' of which the expression is induced in aggressive types of breast cancer and to which both E2F itself and a number of E2F target genes belong (Perou et al., 2000; Sorlie 2004; Whitfield et al., 2006) . Brip1 is therefore not unlikely to belong to this kind of proliferation signature. Whether elevated Brip1 transcript levels indeed correspond with poorer breast cancer outcome, has to be determined by further studies. Higher Brip1 levels in more malignant breast cancers contradict Brip1's function as a tumor suppressor. This 'dual behavior' was also found for example for the Wilms' tumor 1 (WT1) gene, mutations of which can lead to the development of kidney tumors and overexpression of which was detected in different human cancers (reviewed in Yang et al., 2007 ) . Human Brip1 is located at chromosome 17q22-q24, a region that is often amplified in human breast tumors as determined by comparative genomic hybridization. Moreover, amplification of the Brip1 gene itself has been shown in both the MCF7 and the BT474 breast cancer cell lines (reviewed in Sinclair et al., 2003) . Genome copy number abnormalities are known to contribute to breast cancer pathophysiology (Chin et al., 2006) . Interestingly, chromosomal instability in breast cancer is associated with higher transcript levels of genes involved in processes maintaining chromosomal integrity (such as DNA repair, in which Brip1 is also involved) although loss of function for these genes results in higher instability . The majority of these genes are E2F1 targets, which directly links deregulation of E2F/Rb signaling to chromosome instability. In contrast with breast tumors, prostate tumors have lower E2F1 levels and fewer copy number alterations (Paris et al., 2004; Zacharatos et al., 2004) . Interestingly, ER-positive breast carcinomas have a low level of chromosomal instability, whereas ER-negative and high grade specimens have high levels of instability . These findings correspond with the significantly higher Brip1 and E2F1 transcript levels that were found in ER-negative and high grade tumors of our set of 101 primary invasive breast carcinomas. Together, these data confirm the hypothesis that, in addition to loss of function, overexpression of tumor suppressors such as Brip1 can lead to a disequilibrium in fine-tuned processes such as genome integrity maintenance, to genomic instability and contribute to breast cancer malignancy.
In conclusion, we showed that expression of Brip1 is controlled by the E2F/Rb pathway and identified a functional E2F-responsive site in the promoter of both the murine and the human Brip1 gene. In a large set of primary invasive breast carcinomas, significantly higher Brip1 expression was seen in specimens of high grade, ER-negative, PR-negative or HER-2-positive status; clinicopathological parameters that are all correlated with an unfavorable outcome.
Materials and methods
Cell culture
Mouse osteoblastic MC3T3-E1 cells (Riken) and human breast cancer MCF7 cells (ATCC) were grown as previously described (Eelen et al., 2004b; Verlinden et al., 2007) . For serum starvation experiments, cells were seeded without fetal bovine serum for 48 h, after which medium was replaced by medium containing 10% serum. Synchronization of the cells after serum deprivation was determined by FACSort flow cytometry (BD Biosciences, Erembodegem, Belgium; Becton Dickinson) as previously described (Eelen et al., 2004b) . For RNA extractions with RNeasy (Qiagen, Venio, The Netherlands) cells were seeded at 150 000 cells per well or 65 000 cells per well (serum starvation experiments) in 6-well plates. For transfections, cells were seeded at 20 000 (MC3T3-E1) or 50 000 cells per well (MCF7) in 24-well plates. For immunoblotting MCF7 cells were seeded at 1.5 Â 10 6 cells in 10 cm dishes.
Breast carcinoma case selection A total of 101 primary invasive breast carcinomas from postmenopausal women were recruited from the Pathology Department. Inclusion criteria, histopathological examination and assessment of ER, PR and HER-2 expression are described elsewhere . This study was approved by the Local Commission for Medical Ethics and Clinical Studies.
Plasmids and reagentia
A fragment of the 5 0 flanking region of the murine Brip1 gene (À216/ þ 69) and the human Brip1 gene (À252/ þ 100) were PCR amplified and cloned into the pGL3basic luciferase reporter vector (Promega, Leiden, The Netherlands). Mutation of putative E2F binding sites was performed with the QuickChange II Site-Directed Mutagenesis kit (Stratagene, Amsterdam, The Netherlands). The b-galactosidase expression vector pcDNA3.1(À)/Myc-His/lacZ and the vector pcDNA3.1/ Myc-His were purchased from Invitrogen (Merelbeke, Belgium). pcDNA-HA-E2F1, pcDNA-HA-E2F2, pcDNA-HA-E2F3 and pcDNA-HA-E2F4 were obtained from Dr J Nevins (Duke University Medical Center, Durham, NC, USA) and pCMV-HA-E2F5 was obtained from Dr J Magae (Institute of Research and Innovation, Chiba, Japan). 1,25-(OH) 2 D 3 was obtained from JP van de Velde (Solvay, Weesp, The Netherlands).
Transfections
Fugene 6 (Roche Diagnostics, Vilvoorde, Belgium) was used to transfect MC3T3-E1 and MCF7 cells with 100 or 500 ng, respectively of the different Brip1 promoter constructs or with the empty pGL3basic vector as a control, 50 or 250 ng of the different E2F expression constructs or empty pcDNA3.1/MycHis as a control and 10 or 25 ng of the pcDNA3.1(À)/MycHis/lacZ vector. Forty-eight hour after transfection, luciferase and b-galactosidase activity were measured with the Luciferase Assay System (Promega) and the Galacto-Light Plus System (Applied Biosystems, Nieuwerkerk AD IJssel, The Netherlands), respectively. Luciferase activity was normalized to b-galactosidase activity.
Chromatin immunoprecipitation assays
ChIP assays were performed as previously described (Verlinden et al., 2005) . For PCR analysis of ChIP output DNA a primer set around the TSS and a primer set in a distant region (intron 4) of the murine Brip1 gene were used. As a positive control a primer set specific for the murine Cdc6 promoter was used. Sequences of primers are available upon request. Antibodies used for ChIP assays are anti-E2F1 (sc-193x, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and rabbit anti-mouse immunoglobulins (Dako, Heverlee, Belgium).
Quantitative RT-PCR Quantitative reverse transcriptase (qRT)-PCR analyses of serum starved or 1,25-(OH) 2 D 3 -treated MC3T3-E1 and serumstarved MCF7 cells and breast tissue specimens were performed as previously described Eelen et al., 2004b; Verlinden et al., 2007) . Sequences of primers and probes are available upon request.
Immunoblotting and immunohistochemistry
Preparation of whole cell extracts and subsequent western blotting was essentially performed as previously described (Raemaekers et al., 2003) . Antibodies used were anti-Brip1 (B1310; Sigma, Bornem, Belgium) and anti-b-actin (A5441, Sigma).
Paraffin sections from 30 random cases (5 grade 1, 8 grade 2 and 17 grade 3 carcinomas) were used for immunohistochemical staining of Brip1 (LS-C2623 A2, 1/100 diluted; LifeSpan Biosciences, Seattle, USA) and E2F1 (sc-251, 1/100 diluted; Santa Cruz Biotechnology). For Brip1, both the percentage and intensity of nuclear staining was scored on a 0 to 3 þ scale: no staining (0), weak or moderately strong in o 50% (1 þ ), moderately strong in >50% (2 þ ) and strong, intense staining in >50% of tumor cells (3 þ ). For E2F1, the percentage of positively stained tumor nuclei was scored as follows: no staining (0), o10% (1 þ ), 10-20% (2 þ ) and >20% (3 þ ).
Statistical analysis
The software program Statistica (StatSoft Inc.) was used to perform statistical analyses.
